With this, the funding agency requires the proposals to be submitted under this program to focus on the following areas:
|
a) The studies of the pathogenesis, disease severity prediction and diversity of symptoms that affects a patient's cognition, behavior, sleep, renal and pulmonary functions, along with the signs and symptoms of epilepsy and autism
b) The studies regarding the impact of TSC manifestations over the lifespan of a patient
c) The determination of novel strategies for the management and prevention of TSC manifestations including early therapeutic approaches
d) The deep comprehension of the cellular and molecular mechanisms of TSC developmental stages in mammalian and non-mammalian systems
e) Genetic, epigenetic, and non-genetic modifiers of TSC
f) The identification of biomarkers for early detection, prognosis, and prediction of TSC treatment outcomes.
To support this activities covered under this initiative, the Department of Defense is willing to administer funds in the amount of $1,600,000 per year, for a maximum project period of up to 4 years.
Assistant Professors or Lead Professors at Accredited Colleges and Universities are encouraged to submit an application under the 2012 Tuberous Sclerosis Complex Clinical Trial Award Program.
2012 Tuberous Sclerosis Complex Clinical Trial Award Program
Back to Page 1
About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on community grants and health grants. |
Columbus-based Heroes2u Inc., a video chart startup and part of the social entrepreneurship movement, aims to raise millions for charities by providing an affordable chance for access to a charity’s celebrity booster.